Table 3.

Performance of strategies for defining lower PCa risk based on FH and GRS for targeted PCa detection in the placebo arm of PCPT

Criteria for lower risk	# (%) of subjects	PCa				High-grade PCa
		# of men negative	Negative predictive value (NPV)	False negative rate	# (%) of cases missed	# of men negative	Negative predictive value (NPV)	False negative rate	# (%) of cases missed
FH−	3,756(83%)	2876	76.57%	23.43%	880(79.71%)	3583	95.39%	4.61%	173(79.72%)
GRS<0.6	1,076(24%)	894	83.09%	16.91%	182(16.49%)	1036	96.28%	3.72%	40(18.43%)
FH− and GRS<0.6	922(20%)	766	83.08%	16.92%	156(14.13%)	887	96.20%	3.80%	35(16.13%)

PCPT: Prostate Cancer Prevention Trial

PCa: Prostate cancer

FH: Family history

GRS: Genetic risk score

High-grade PCa is defined as PCa with Gleason score ≥7